ACP
SGMO

Acuta Capital Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Acuta Capital Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$950K – 71
2018
Q1 		$950K Buy
+50,000
New +$1.07M 0.16% 47
2017
Q3 		– Sell
-30,000
Closed -$264K – 75
2017
Q2 		$264K Buy
+30,000
New +$192K 0.07% 55

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acuta Capital Partners's SGMO Position: Q1 2025 in Review

Acuta Capital Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 740,000 shares — an estimated $755K sold.

Acuta Capital Partners first reported a position in SGMO in Q4 2024 and held it in 1 quarter. The position peaked at $755K in Q4 2024. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Acuta Capital Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 740,000 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $755K.
  • Acuta Capital Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and held it in 1 quarter.
  • Acuta Capital Partners's SANGAMO THERAPEUTICS INC position peaked at $755K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.